SCHOTT Pharma AG & Co. KGaA (BIT:1SXP)
Italy · Delayed Price · Currency is EUR | Market Cap | 2.05B -45.7% |
| Revenue (ttm) | 995.03M +4.1% |
| Net Income | 149.95M +11.1% |
| EPS | 0.99 +10.0% |
| Shares Out | n/a |
| PE Ratio | 13.64 |
| Forward PE | 13.93 |
| Dividend | 0.18 (1.17%) |
| Ex-Dividend Date | Feb 4, 2026 |
| Volume | n/a |
| Average Volume | 2 |
| Open | 15.44 |
| Previous Close | 15.44 |
| Day's Range | 15.44 - 15.44 |
| 52-Week Range | 13.70 - 30.40 |
| Beta | n/a |
| RSI | 39.16 |
| Earnings Date | Feb 11, 2026 |
About BIT:1SXP
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold application... [Read more]
Financial Performance
In fiscal year 2025, BIT:1SXP's revenue was 986.21 million, an increase of 3.04% compared to the previous year's 957.09 million. Earnings were 146.45 million, a decrease of -2.16%.
Financial StatementsNews
EQS-DD: SCHOTT Pharma AG & Co. KGaA: Dr. Torsten Derr, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 12.02.2026 / 11:32 CET/CEST The issuer is solely responsi...